FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Vienot, Angélique; Chevalier, Hortense; Bolognini, Clément; Gherga, Elisabeta; Klajer, Elodie; Meurisse, Aurélia; Jary, Marine; Kim, Stefano; d'Engremont, Christelle; Nguyen, Thierry; Calcagno, Fabien; Almotlak, Hamadi; Fein, Francine; Nasri, Meher; Abdeljaoued, Syrine; Turpin, Anthony; Borg, Christophe; Vernerey, Dewi

doi:10.4251/wjgo.v12.i3.332

Public

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Shared by NobleBlocks on Mar 15, 2020 • 12:00 AM UTC

Authors:

Angélique Vienot

Hortense Chevalier

Clément Bolognini

Abstract

BACKGROUND: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer. AIM: To investigate th...

Subject

Advanced pancreatic cancer

Cohort study

FOLFIRINOX

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!